Ras oncogene mutations and survival in patients with lung cancer
2006
Ras Mutations and Lung Cancer Survival
Sample size: 36
publication
Evidence: moderate
Author Information
Author(s): Ferretti G, Felici A, Cognetti F
Primary Institution: Regina Elena Cancer Institute
Hypothesis
What is the prognostic significance of ras mutations in lung cancer survival?
Conclusion
Ras mutations may be a poor prognostic factor for survival in non-small-cell lung cancer, but results are inconsistent.
Supporting Evidence
- Ras mutations were found in 19.4% of patients with non-small-cell lung cancer.
- Ras gene alteration appears to be a poor prognostic factor for survival in NSCLC.
- Patients with K-ras mutant NSCLC showed poorer clinical outcomes when treated with erlotinib and chemotherapy.
- In some studies, K-ras mutations were not predictive markers of shorter survival.
Takeaway
Some lung cancer patients have a gene change called ras that might make their cancer worse, but scientists are still figuring out how important it is.
Methodology
Data from retrospective trials and univariate analysis were aggregated.
Limitations
The prognostic significance of ras mutations remains controversial and needs further confirmation in prospective trials.
Participant Demographics
Patients with primary operable non-small-cell lung cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website